Paul Conyngham, an Australian tech entrepreneur who previously gained attention for using AI tools like ChatGPT and Grok to create a personalized cancer vaccine for his dog, Rosie, has officially launched a biotechnology startup named Gamgee. The company aims to provide personalized mRNA cancer vaccines specifically for canine patients.

While the project began as a personal effort to treat his own pet, Conyngham’s business plans for Gamgee are significantly broader. According to the company’s website, the startup intends to leverage artificial intelligence and genetic research to develop medical treatments for a variety of diseases across multiple species. Conyngham has explicitly stated that the company’s long-term ambitions include developing therapeutic applications for humans.

The transition from a DIY AI project to a commercial startup highlights the growing intersection of generative AI and biotechnology. However, the venture has drawn attention for its rapid evolution from a singular, anecdotal case study involving a pet to a broader medical platform. While the initial story focused on the accessibility of AI tools in medical research, the launch of Gamgee shifts the focus toward the regulatory and scientific challenges of scaling personalized mRNA treatments for veterinary and human use.